Stocks › ARWR
Arrowhead Pharmaceuticals ARWR
US equityMarket cap rank #1888
$41.37 −$2.28 (-5.22%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $41.40 +0.07%
Open$43.15
Prev close$43.65
Day range$41.17 – $44.80
Volume3.91M
Market cap$5.85B
P/E (TTM)–
Dividend yield–
Earnings
Average move on report day±9.7%last 16 reports
Closed higher8 of 1650% of the time
Best reaction+24.2%
Worst reaction-26.8%
Stock move on the day after each report
| Quarter | Report date | Timing | Implied move | Actual move | Versus implied |
|---|---|---|---|---|---|
| 2026/Q4 | 12 Nov 2026 | After Market | ±8.5% | +1.34% | Within range |
| 2026/Q3 | 4 Aug 2026 | After Market | ±8.9% | -2.99% | Within range |
| 2026/Q2 | 7 May 2026 | After Market | ±7.3% | -6.75% | Within range |
| 2026/Q1 | 5 Feb 2026 | After Market | ±11.9% | -0.19% | Within range |
| 2025/Q4 | 25 Nov 2025 | After Market | ±13.5% | +23.34% | Bigger than priced |
| 2025/Q3 | 7 Aug 2025 | After Market | ±13.3% | +2.24% | Within range |
| 2025/Q2 | 12 May 2025 | After Market | ±12.0% | +9.38% | Within range |
| 2025/Q1 | 10 Feb 2025 | After Market | ±10.8% | -5.17% | Within range |
| 2024/Q4 | 26 Nov 2024 | After Market | ±15.0% | +24.23% | Bigger than priced |
| 2024/Q3 | 8 Aug 2024 | After Market | ±12.7% | -9.44% | Within range |
| 2024/Q2 | 9 May 2024 | After Market | ±10.4% | -10.68% | Bigger than priced |
| 2023/Q4 | 29 Nov 2023 | After Market | ±12.0% | -26.85% | Bigger than priced |
| 2023/Q3 | 7 Aug 2023 | After Market | ±8.9% | -10.78% | Bigger than priced |
| 2023/Q2 | 2 May 2023 | After Market | ±16.4% | +13.62% | Within range |
| 2023/Q1 | 6 Feb 2023 | After Market | ±14.3% | +0.33% | Within range |
| 2022/Q4 | 28 Nov 2022 | After Market | ±20.5% | +7.11% | Within range |
"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.
Fundamentals
Latest reported quarter: Q4, ended Sep 2026
Revenue$37.79M-85.3% YoY
Operating profit-$436.63M-1,089.9% YoY
Net profit-$428.89M-2,760.4% YoY
Diluted EPS-$3.01-1,572.2% YoY
Free cash flow-$195.83M-1,606.2% YoY
Operating cash flow-$192.40M
Revenue, last 8 quarters
Net profit, last 8 quarters
Profitability & balance sheet
Gross margin99.6%
Operating margin-156.9%
Net margin-160.6%
Return on equity-280.5%
Return on assets-46.4%
Return on invested capital-73.2%
Current ratio4.14
Liabilities / assets97.1%
Cash & investments$1.19B
Total debt$994.70M
Net cash (debt)$198.29M
No comments yet — be the first to weigh in on ARWR.
Sign in to join the discussion.